粒细胞-巨噬细胞刺激因子辅助治疗急性骨髓性白血病的系统评价

Granulocyte Macrophage Colony Stimulating Factor as an Adjunctive Therapy for Acute Myeloid Leukemia:A Systematic Evaluation

目的:评价粒细胞-巨噬细胞刺激因子(GM-CSF)辅助治疗急性骨髓性白血病(AML)的疗效。方法:计算机检索PubMed、EMBase、CBMdisc、CNKI数据库及Cochrane图书馆,手工检索其它白血病相关杂志,对纳入的GM-CSF治疗AML的随机对照试验(RCT)进行方法学质量评价,并用RevMan5.0软件进行Meta分析。结果:共纳入10个RCT,A、B、C级文章分别有3篇、5篇、2篇。分析结果显示,完全缓解率、复发率、感染率、住院时间等指标的组间差异均无统计学意义。结论:基于现有临床研究结果,GM-CSF不能提高患者完全缓解率,亦不能降低复发率、感染率和缩短住院时间。

OBJECTIVE： To evaluate the curative efficacy of granulocyte macrophage colony stimulating factor （GM- CSF） as an adjunctive therapy for the treatment of acute myeloid leukemia （AML）. METHODS： Randomized controlled trials （RCTs） of GM - CSF in the treatment of AML were retrieved from PubMed, EMBase, Cochrane Library, CBMdisc and CNKI database by computer as well as from the leukemia - related journals manually for a quality evaluation of the methodology and Meta analysis using RevMan5.0 software. RESULTS： A total of 10 RCTs were included, of which, 3 RCTs were graded as A, 5 as B and 2 as C. The results demonstrated that there were no significant differences of indexes among groups as complete remission （CR） rate, relapse rate, infection rate and length of hospital stay, etc. CONCLUSION： The available clinical research results showed that GM-CSF adjunctive therapy could neither increase CR rate, nor decrease the relapse rate, infection rate or length of hospital stay.